The company announced its first clinical location in December with the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) authorizing Alterity to commence recruitment in that country. This is the first jurisdiction to authorize the trial with further countries to follow in 2022. The trial expected to open for enrollment in the first quarter of CY 2022.
I am not sure why they had changed the statement from "commence trial" to "open for enrollment"... The trial is considered as commenced only if first patient is dosed. IMO, I am afraid this indicates further delay in the process....
Volumes are down, page-2
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $5.503K | 1.808M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 46 | 56169934 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 122932868 | 20 |
View Market Depth
| Last trade - 12.21pm 03/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |